EUVIMEDEUVIMED entdecken
Crossref

Quantification of Amlexanox in Beagle Dog Plasma by LC–MS/MS and Its Application in a Comparative Pharmacokinetic Study of Conventional and Sustained‐Release Tablets

Yanmei Yi iD, Wei He, Xiaochen Niu, Jianchun Zhao iD

Biomedical Chromatography · 2026

DOI: 10.1002/bmc.70625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2026. Verfasst von Yanmei Yi und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Pharmacy, Ocean University of China, Qingdao, China. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry, Aminopyridines, 4-Aminopyridine. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amlexanox, a 5H‐benzopyranopyridine derivative with emerging therapeutic potential in metabolic and inflammatory diseases, lacks a validated analytical method for pharmacokinetic studies in beagle dogs. A sensitive LC–MS/MS method was developed and validated for amlexanox in beagle dog plasma according to ICH M10 guidelines. Propranolol served as internal standard. Samples were processed by protein precipitation, and separation was achieved on a CAPCELL PAK C18 column using gradient elution with water and acetonitrile (both containing 0.2% formic acid) at 400 μL/min. Detection used positive electrospray ionization with MRM of m/z 299.0 → 281.0 for amlexanox and m/z 260.0 → 116.1 for IS. The method showed good linearity over 40–2000 ng/mL ( R 2 > 0.99). All validation parameters met acceptance criteria. The method was applied to a three‐period fixed‐sequence study in beagle dogs ( n = 3, male) comparing intravenous injection (1 mg/kg), conventional tablets (75 mg), and sustained‐release tablets (150 mg). The sustained‐release formulation prolonged T max (3.67 vs. 1.00 h) and residence time (two‐fold increase in t 1/2 and MRT), and improved absolute bioavailability from 25.36% to 33.09% (relative bioavailability: 151.30%). These findings support the clinical development of a sustained‐release amlexanox formulation with reduced dosing frequency and improved patient compliance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryLiquid Chromatography-Mass SpectrometryAminopyridines4-AminopyridineAnimalsDogsReproducibility of ResultsLinear ModelsMaleTabletsDelayed-Action PreparationsLimit of DetectionSensitivity and SpecificityChromatography, Liquid

Stichwörter der Autor:innen

LC–MS/MSamlexanoxbeagle dogpharmacokineticssustained‐release tablet

Substanzen

TabletsDelayed-Action PreparationsamlexanoxAminopyridines4-Aminopyridine

Autor:innen und Institutionen

  • School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
  • Marine Biomedical Research Institute of Qingdao, Ocean University of China, Qingdao, China.

ORCID-Profile: Yanmei Yi, Jianchun Zhao

Zitieren

APA

Yi, Y., He, W., Niu, X., & Zhao, J. (2026). Quantification of Amlexanox in Beagle Dog Plasma by LC–MS/MS and Its Application in a Comparative Pharmacokinetic Study of Conventional and Sustained‐Release Tablets. Biomedical Chromatography. https://doi.org/10.1002/bmc.70625

Vancouver

Yi Y, He W, Niu X, Zhao J. Quantification of Amlexanox in Beagle Dog Plasma by LC–MS/MS and Its Application in a Comparative Pharmacokinetic Study of Conventional and Sustained‐Release Tablets. Biomedical Chromatography. 2026. doi:10.1002/bmc.70625

BibTeX
@article{Yi2026,
  author = {Yi, Yanmei and He, Wei and Niu, Xiaochen and Zhao, Jianchun},
  title = {Quantification of Amlexanox in Beagle Dog Plasma by LC–MS/MS and Its Application in a Comparative Pharmacokinetic Study of Conventional and Sustained‐Release Tablets},
  journal = {Biomedical Chromatography},
  year = {2026},
  doi = {10.1002/bmc.70625}
}
Kostenlos starten →